The Korea Technology Finance Corporation (Korea Technology Finance Corporation, Chairman Kim Jong-ho, hereinafter referred to as KIBO) announced on the 10th that it selected Jinseeker Co., Ltd. (Co-CEOs Ye Seong-hyeok and Heo Jun-seok) as an 'IP-Value Powerhouse' and supported KRW 1 billion in Excellent IP Value Plus Guarantee (hereinafter referred to as Value Plus Guarantee) by reflecting the results of the value assessment of its patented technology 'Mutant Cell-Free Gene Isolation Kit and Mutant Cell-Free Gene Isolation Method Using the Same'.
The Value Plus Guarantee is a customized guarantee product that discovers excellent IPs in high value-added cutting-edge technology fields among the intellectual property (IP) owned by small and medium-sized enterprises and provides commercialization funds by linking them with guarantees within the calculated value amount. Kibo is awarding the 'IP-Value Powerhouse Small and Medium-sized Enterprise' certificate to excellent IP companies selected through high-difficulty technology value evaluation, and held an award ceremony on the 10th at Kibo Central Technology Evaluation Institute in Yangjae-dong, Seoul, with the attendance of CEO Jin Seeker.
Jinseeker Co., Ltd. is a small and medium-sized enterprise established in November 2017 by CEO Yesunghyuk. It has developed a genetic pre-screening technology based on the third-generation gene scissors CRISPR-Cas9 and provides cancer diagnostic kits and genetic analysis services to medical institutions at home and abroad. In particular, this technology is recognized for its technological differentiation in that it can detect circulating tumor DNA more easily than before in the blood cancer gene analysis and diagnosis process and can be applied to various types of cancer.
Kibo highly evaluated the technological prowess and business growth potential of Jinseeker Co., Ltd. and provided a value plus guarantee of 1 billion won. It also plans to actively support the commercialization of excellent IPs by providing various benefits such as ▲guarantee fee reduction ▲free support for pre-diagnosis evaluation for technology special listing ▲technology evaluation certification for investment purposes.
Lee Jae-pil, CEO of Kibo, said, “Despite possessing excellent IP, domestic bio venture companies are taking a long time to develop and prepare for commercialization, and are experiencing many difficulties in raising funds due to the recent contraction of the investment market.” He added, “Going forward, Kibo will do its best to actively discover bio venture companies with excellent IP and link them with customized policies such as R&D and infrastructure support so that they can secure technological competitiveness in the global market.”
- See more related articles
You must be logged in to post a comment.